Thursday, August 01, 2024 5:18:47 PM
You can BS and gaslight as much as you want about Flaskworks but there may be quite a few folks who are waiting for UK approval pump to get out or exit a significant portion of their investment. These folks are not going to wait for Flaskworks. It would be stupid to hold on if a big pharma partner is not revealed at UK approval.
Without non dilutive cash injection, this will take 3-4 years before we get any traction. This management is not capable of building shareholder value over an extended duration, so why would you not sell if and when the opportunity presents itself at the UK approval.
Flaskworks may be another 18 months at the very least before it gets approved for commercial use. More importantly, there is a large degree of uncertainty around approvals of Flaskworks. Forget about timing in terms of whether that takes 12, 18 or 24 months from now. They haven’t reported any successful validation runs. It will be another year after that before we get approval. And what if validation run doesn't go according to plan?
Most people value opportunity cost!
Without non dilutive cash injection, this will take 3-4 years before we get any traction. This management is not capable of building shareholder value over an extended duration, so why would you not sell if and when the opportunity presents itself at the UK approval.
Flaskworks may be another 18 months at the very least before it gets approved for commercial use. More importantly, there is a large degree of uncertainty around approvals of Flaskworks. Forget about timing in terms of whether that takes 12, 18 or 24 months from now. They haven’t reported any successful validation runs. It will be another year after that before we get approval. And what if validation run doesn't go according to plan?
Most people value opportunity cost!
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
